Immunology Investor Event

Blazing the trail with DupixentⓇ in priority areas Type 2 A Dermatology Atopic dermatitis DUPIXENTⓇ (dupilumab) Respiratory Asthma COPD DUPIXENTⓇ (dupilumab) Beyond Type 2 4+ Injectables Orals ✓ Topical DupixentⓇ is under investigation in COPD, EoE and in infant population in AD, and not yet approved by any regulatory agency to treat these indications 14 Immunology Investor Event 凹 sanofi Gastroenterology EOE or UC DUPIXENT® (dupilumab)

View entire presentation